News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

uniQure Announces Analysis Of Six-Year Follow-Up Data For Glybera®


6/3/2014 10:50:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AMSTERDAM, The Netherlands, June 3, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the full analysis of the six-year follow-up data for patients treated once with Glybera® (alipogene tiparvovec), uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency (LPLD). Dr. Daniel Gaudet, the leading investigator during the majority of the clinical studies performed with Glybera, presented the results at the 82nd Annual Congress of the European Atherosclerosis Society (EAS) held in Madrid, Spain. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal. LPLD patients eligible for Glybera treatment suffer from reoccurring and often severe pancreatitis events leading to recurrent admissions to hospitals and intensive care units (ICUs).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES